Clinuvel Pharmaceuticals Ltd

CUV

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    16

Stocks News & Analysis

stocks

Undervalued ASX biotech

Despite improving prospects the shares continue to sell off.
stocks

Undervalued ASX listed biotech refocuses

Fair value uneffected by suspended early-stage clinical trials.
funds

10 reasons many fund managers are now blank spaces

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,941.1234.54-0.38%
HKSE24,139.57111.200.46%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,259.7520.71-0.33%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers